Bayer Signs a License Agreement with Sensible Medical for its ReDS Technology in Europe

 Bayer Signs a License Agreement with Sensible Medical for its ReDS Technology in Europe

Bayer Signs a License Agreement with Sensible Medical for its ReDS Technology in Europe

Shots:

  • Bayer will utilize Sensible’s ReDS technology as a biomarker for monitoring lung congestion in a clinical study for patients with heart failure, making Bayer, Sensible’s largest customer in Europe
  • The ReDS System is used as Point-of-Care device/marker of lung fluid, producing a Continuum of Care for patients with fluid management problems + HF/ recovering from coronary artery diseases
  • The ReDS System is a wearable vest, quantifying the amount of lung fluid non-invasively and has received FDA’s 510 (k) & CE marking, currently being commercialized in the US

Click here to read full press release/ article | Ref: PRNewsWire | Image: Retail Design Blog

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post